In the last years, preclinical and clinical research focused on targeting different pathways involved in tumor growth, such as PI3K/Akt/mTOR, cyclinD/CDK/pRb pathways and tumor microenvironment [103,105,106]. Here, RB1 is linked to neoplasm.